Get access

The role of diagnosis in patients failing peripheral blood progenitor cell mobilization


  • Disclaimer: Part of the work presented has been supported by Amgen, Inc. There is, however, no personal or institutional dependency arising from this relationship nor any agreement to exclusively prescribe the medication that was tested.

M. Koenigsmann, Klinik für Hämatologie und Onkologie, Otto-von-Guericke-Universität, Leipziger Strasse 44, 39120 Magdeburg, Germany; e-mail:


BACKGROUND: Failure to mobilize PBPCs for auto-logous transplantation has mostly been attributed to previous therapy and poses therapeutic problems.

STUDY DESIGN AND METHODS: The role of underlying disease was analyzed in 17 of 73 (23%) patients with PBPC mobilization failure, and secondary mobilization with high-dose filgrastim was attempted.

RESULTS: Of 16 patients with acute leukemia, 13 (81%) mobilized poorly. In contrast, of 57 patients with non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, and solid tumor, 53 (93%, p < 0.001) showed good PBPC mobilization. Relapsed disease did not predispose to poor mobilization. As secondary mobilization attempt, 7 patients received 25 µg per kg per day filgrastim without chemotherapy leading to a 3.7 ± 2.8-fold (SD) increase in the maximum number of circulating CD34+ cells (p = 0.104). PBPC apheresis yielded 3.3 (±0.5) × 106 CD34+ cells per kg of body weight in 5 patients. Four poor mobilizers received 50 µg per kg per day filgrastim as second or third mobilization attempt. Circulating CD34+ cells in these patients increased by 1.5 (±0.7) compared with the primary G–CSF application.

CONCLUSION: Selective PBPC mobilization failure was seen in patients with acute leukemia whereas remarkably good mobilization was seen in other malignancies. Increasing the filgrastim dose to 25 µg per kg per day may allow PBPC collection in patients failing PBPC mobilization.